Steven Joffe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2714459/publications.pdf

Version: 2024-02-01

213

papers

12,764

citations

28242

55

h-index

26591

107

g-index

219

all docs

219

docs citations

219

times ranked

17417

citing authors

#	ARTICLE	IF	CITATIONS
1	Patients' roles in governance of learning: Results from a qualitative study of 16 learning healthcare systems. Learning Health Systems, 2022, 6, e10269.	1.1	2
2	Perceived Utility of Genomic Sequencing: Qualitative Analysis and Synthesis of a Conceptual Model to Inform Patient-Centered Instrument Development. Patient, 2022, 15, 317-328.	1.1	21
3	How neonatologists use genetic testing: findings from a national survey. Journal of Perinatology, 2022, 42, 260-261.	0.9	5
4	Health Literacy and Clinical Outcomes Following Hematopoietic Stem-Cell Transplantation. JCO Oncology Practice, 2022, , OP2100049.	1.4	1
5	Influence of Genetic Information on Neonatologistsâ€™ Decisions: A Psychological Experiment. Pediatrics, 2022, 149, .	1.0	12
6	Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research. Annals of Internal Medicine, 2021, 174, 256-257.	2.0	2
7	The limits of acceptable political influence over the FDA. Nature Medicine, 2021, 27, 188-190.	15.2	7
8	Allocating scarce life-saving resources: the proper role of age. Journal of Medical Ethics, 2021, 47, 836-838.	1.0	8
9	Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. Journal of Infectious Diseases, 2021, 224, 1995-2000.	1.9	19
10	Historical trends in health care-related financial holdings among members of Congress. PLoS ONE, 2021, 16, e0253624.	1.1	0
11	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplantation, 2020, 55, 906-917.	1.3	33
12	Rethinking ethical oversight in the era of the learning health system. Healthcare, 2020, 8, 100462.	0.6	7
13	Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents. BMC Pediatrics, 2020, 20, 222.	0.7	11
14	The Importance of Engaging Children in Research Decisionâ€Making: A Preliminary Mixedâ€Methods Study. Ethics & Human Research, 2020, 42, 12-20.	0.5	4
15	Prescription Requirements and Patient Autonomy: Considering an Over-the-Counter Default. Hastings Center Report, 2020, 50, 15-26.	0.7	2
16	Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight. JAMA - Journal of the American Medical Association, 2019, 322, 1553.	3.8	6
17	Response to Open Peer Commentaries: When Is It Ethical for Physician-Investigators to Seek Consent From Their Own Patients?. American Journal of Bioethics, 2019, 19, W3-W4.	0.5	3
18	Consent insufficient for data release. Science, 2019, 364, 445-446.	6.0	9

#	ARTICLE	IF	CITATIONS
19	When Is It Ethical for Physician-Investigators to Seek Consent From Their Own Patients?. American Journal of Bioethics, 2019, 19, 11-18.	0.5	44
20	Patient-Physician Relationship in the Age of Expanded Access to Informationâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1633.	3.8	0
21	Challenges in Research on Suicide Preventionâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1105.	3.8	0
22	The Multidimensional Illness Severity Questionnaire: Preliminary evaluation of a brief parentâ€reported measure of illness severity. Journal of Paediatrics and Child Health, 2019, 55, 1241-1246.	0.4	2
23	Concurrent and Overlapping Surgery. Spine, 2019, 44, 53-59.	1.0	12
24	Consent for clinical genome sequencing: considerations from the Clinical Sequencing Exploratory Research Consortium. Personalized Medicine, 2019, 16, 325-333.	0.8	8
25	Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs. JAMA - Journal of the American Medical Association, 2018, 319, 2167.	3.8	7
26	Gender and Byline Placement of Co-first Authors in Clinical and Basic Science Journals With High Impact Factors. JAMA - Journal of the American Medical Association, 2018, 319, 610.	3.8	39
27	Federal Right-to-Try Legislation â€” Threatening the FDAâ€™s Public Health Mission. New England Journal of Medicine, 2018, 378, 695-697.	13.9	39
28	The benefit sharing vision of H3Africa. Developing World Bioethics, 2018, 18, 165-170.	0.6	12
29	Characteristics Associated With Preferences for Parent-Centered Decision Making in Neonatal Intensive Care. JAMA Pediatrics, 2018, 172, 461.	3.3	37
30	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. Journal of Clinical Oncology, 2018, 36, 3331-3339.	0.8	58
31	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. PLoS ONE, 2018, 13, e0203179.	1.1	5
32	Will my child do better if she enrolls in a clinical trial?. Cancer, 2018, 124, 3965-3968.	2.0	3
33	Implications of Zero Suicide for Suicide Prevention Research. JAMA - Journal of the American Medical Association, 2018, 320, 1633.	3.8	30
34	Informed Consent and the Role of the Treating Physician. New England Journal of Medicine, 2018, 379, e25.	13.9	3
35	The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. Human Mutation, 2018, 39, 1713-1720.	1.1	102
36	The New Age of Patient Autonomy. JAMA - Journal of the American Medical Association, 2018, 320, 1973.	3.8	82

#	ARTICLE	IF	CITATIONS
37	Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. JAMA Oncology, 2018, 4, 1041.	3.4	4
38	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2145-2151.	2.0	14
39	Including all voices in international data-sharing governance. Human Genomics, 2018, 12, 13.	1.4	50
40	Informed Consent and the Role of the Treating Physician. New England Journal of Medicine, 2018, 378, 2433-2438.	13.9	20
41	A taxonomy of medical uncertainties in clinical genome sequencing. Genetics in Medicine, 2017, 19, 918-925.	1.1	91
42	Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest. JAMA Internal Medicine, 2017, 177, 344.	2.6	93
43	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine, 2017, 19, 787-795.	1.1	46
44	Ethical considerations in genomic testing for hematologic disorders. Blood, 2017, 130, 460-465.	0.6	22
45	From Sequence Data to Returnable Results: Ethical Issues in Variant Calling and Interpretation. Genetic Testing and Molecular Biomarkers, 2017, 21, 178-183.	0.3	5
46	Justifying Clinical Nudges. Hastings Center Report, 2017, 47, 32-38.	0.7	33
47	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine, 2017, 14, 37-50.	0.8	15
48	Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives. Journal of Law, Medicine and Ethics, 2017, 45, 375-381.	0.4	2
49	Justification and authority in institutional review board decision letters. Social Science and Medicine, 2017, 194, 25-33.	1.8	19
50	Reframing Consent for Clinical Research: A Function-Based Approach. American Journal of Bioethics, 2017, 17, 3-11.	0.5	176
51	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. Trials, 2017, 18, 474.	0.7	5
52	Implementing cost transparency in oncology: A qualitative study of barriers, facilitators, and patient preferences.. Journal of Clinical Oncology, 2017, 35, 6597-6597.	0.8	5
53	Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Medicine, 2017, 14, e1002190.	3.9	62
54	Ethics knowledge of recent paediatric residency graduates: the role of residency ethics curricula. Journal of Medical Ethics, 2016, 42, 809-814.	1.0	14

#	ARTICLE	IF	CITATIONS
55	A Flawed Revision of the Common Rule. Annals of Internal Medicine, 2016, 165, 143.	2.0	4
56	Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. American Journal of Bioethics, 2016, 16, 3-11.	0.5	35
57	When Participants in Genomic Research Grow Up: Contact and Consent atÂthe Age of Majority. Journal of Pediatrics, 2016, 168, 226-231.e1.	0.9	17
58	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. AJOB Empirical Bioethics, 2016, 7, 106-115.	0.8	16
59	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	2.6	137
60	Parental Decision-Making Preferences in Neonatal Intensive Care. Journal of Pediatrics, 2016, 179, 36-41.e3.	0.9	49
61	Procedure-specific consent is the norm in United States intensive care units. Intensive Care Medicine, 2016, 42, 1637-1638.	3.9	3
62	Trials Infrastructure as Good Old-Fashioned Health System Strengthening. American Journal of Bioethics, 2016, 16, W3-W5.	0.5	1
63	The Ethics of Infection Challenges in Primates. Hastings Center Report, 2016, 46, 20-26.	0.7	14
64	Oncologistsâ€™ and cancer patientsâ€™ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine, 2016, 18, 1011-1019.	1.1	108
65	An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer. Journal of the National Cancer Institute, 2016, 108, djv392.	3.0	28
66	The Role of Patient Perspectives in Clinical Research Ethics and Policy: Response to Open Peer Commentaries on â€œPatient Perspectives on the Learning Health Systemâ€. American Journal of Bioethics, 2016, 16, W7-W9.	0.5	1
67	Deliberations of a precision medicine tumor board.. Journal of Clinical Oncology, 2016, 34, e13005-e13005.	0.8	1
68	Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities.. Journal of Clinical Oncology, 2016, 34, 1500-1500.	0.8	2
69	Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine.. Journal of Clinical Oncology, 2016, 34, 11565-11565.	0.8	0
70	Child and Parent Understanding of Clinical Trials: The Semi-Structured Comprehension Interview. AJOB Empirical Bioethics, 2015, 6, 23-32.	0.8	4
71	Investigator Experiences and Attitudes About Research With Biospecimens. Journal of Empirical Research on Human Research Ethics, 2015, 10, 449-456.	0.6	6
72	Attitudes Toward Risk and Informed Consent for Research on Medical Practices. Annals of Internal Medicine, 2015, 162, 690-696.	2.0	87

#	Article	IF	Citations
73	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq1 1 0.784314 rgBT /Overlock	3.0	27
74	Reply to S. Gupta et al. Journal of Clinical Oncology, 2015, 33, 1414-1414.	0.8	9
75	Physicians and Insider Trading. JAMA Internal Medicine, 2015, 175, 1955.	2.6	4
76	Gatekeepers for pragmatic clinical trials. Clinical Trials, 2015, 12, 442-448.	0.7	32
77	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biology of Blood and Marrow Transplantation, 2015, 21, 1308-1314.	2.0	45
78	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1815-1822.	2.0	13
79	Clinical research: Should patients pay to play?. Science Translational Medicine, 2015, 7, 298ps16.	5.8	22
80	Commentary on Hey and Kimmelman. Clinical Trials, 2015, 12, 116-118.	0.7	14
81	Ethical Testing of Experimental Ebola Treatmentsâ€"Reply. JAMA - Journal of the American Medical Association, 2015, 313, 422.	3.8	1
82	Knowledge of Pediatric Ethics: Results of a Survey of Pediatric Ethics Consultants. AJOB Empirical Bioethics, 2015, 6, 19-30.	0.8	2
83	Patient Perspectives on the Learning Health System: The Importance of Trust and Shared Decision Making. American Journal of Bioethics, 2015, 15, 4-17.	0.5	94
84	IRB practices and policies regarding the secondary research use of biospecimens. BMC Medical Ethics, 2015, 16, 32.	1.0	21
85	Promoting Informed Decision Making for Comparative Effectiveness Randomized Trials. JAMA Pediatrics, 2015, 169, 803.	3.3	12
86	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	2.4	313
87	Professionally Responsible Disclosure of Genomic Sequencing Results in Pediatric Practice. Pediatrics, 2015, 136, e974-e982.	1.0	28
88	Are hybrid umbilical cord blood banks really the best of both worlds?. Journal of Medical Ethics, 2015, 41, 272-275.	1.0	12
89	Institutional Oversight of Faculty-Industry Consulting Relationships in U.S. Medical Schools: A Delphi Study. Journal of Law, Medicine and Ethics, 2015, 43, 383-96.	0.4	5
90	Evidence, Errors, and Ethics. Perspectives in Biology and Medicine, 2014, 57, 299-307.	0.3	5

#	ARTICLE	IF	CITATIONS
91	Ethics of Cancer Clinical Trials in Low-Resource Settings. Journal of Clinical Oncology, 2014, 32, 3192-3196.	0.8	11
92	Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. Trials, 2014, 15, 384.	0.7	24
93	Addressing the Ethical Challenges in Genetic Testing and Sequencing of Children. American Journal of Bioethics, 2014, 14, 3-9.	0.5	90
94	Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Childrenâ€™s Hospital Gene Partnership Informed Cohort Oversight Board. Genetics in Medicine, 2014, 16, 547-552.	1.1	49
95	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine, 2014, 16, 727-735.	1.1	60
96	The Challenge of Informed Consent and Return of Results in Translational Genomics: Empirical Analysis and Recommendations. Journal of Law, Medicine and Ethics, 2014, 42, 344-355.	0.4	63
97	A Systematic Review of State and Manufacturer Physician Payment Disclosure Websites: Implications for Implementation of the Sunshine Act. Journal of Law, Medicine and Ethics, 2014, 42, 208-219.	0.4	12
98	Deliberation and the Life Cycle of Informed Consent. Hastings Center Report, 2014, 44, 33-35.	0.7	4
99	Evaluating Novel Therapies During the Ebola Epidemic. JAMA - Journal of the American Medical Association, 2014, 312, 1299.	3.8	63
100	Communicating About Prognosis: Ethical Responsibilities of Pediatricians and Parents. Pediatrics, 2014, 133, S24-S30.	1.0	103
101	Chemotherapy Parity Laws. JAMA Internal Medicine, 2014, 174, 1721.	2.6	11
102	Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 829-836.	2.0	43
103	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	2.6	342
104	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 311-321.	13.9	1,387
105	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	15.2	508
106	Chemotherapy Drug Shortages in Pediatric Oncology: A Consensus Statement. Pediatrics, 2014, 133, e716-e724.	1.0	41
107	Hospital Length of Stay in the First 100ÂDays after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 2014, 20, 1819-1827.	2.0	43
108	Cancer patientsâ€™ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study.. Journal of Clinical Oncology, 2014, 32, 1535-1535.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Low health literacy and its correlates among allogeneic bone marrow transplant recipients.. Journal of Clinical Oncology, 2014, 32, e17565-e17565.	0.8	1
110	A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. New England Journal of Medicine, 2013, 369, 341-350.	13.9	1,005
111	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. Biology of Blood and Marrow Transplantation, 2013, 19, 1116-1123.	2.0	104
112	Clinical Trial Participation among Ethnic/Racial Minority and Majority Patients with Advanced Cancer: What Factors Most Influence Enrollment?. Journal of Palliative Medicine, 2013, 16, 256-262.	0.6	28
113	A Prescription for Ethical Learning. Hastings Center Report, 2013, 43, S28-S29.	0.7	18
114	Prevalence of Hematopoietic Cell Transplant Survivors in the United States. Biology of Blood and Marrow Transplantation, 2013, 19, 1498-1501.	2.0	210
115	Experiences and attitudes of genome investigators regarding return of individual genetic test results. Genetics in Medicine, 2013, 15, 882-887.	1.1	44
116	Phase 1 oncology trials and informed consent. Journal of Medical Ethics, 2013, 39, 761-764.	1.0	28
117	The OHRP and SUPPORT. New England Journal of Medicine, 2013, 368, e36.	13.9	57
118	RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials. Journal of the National Cancer Institute, 2013, 105, 993-993.	3.0	0
119	Ethical Issues for Control-Arm Patients After Revelation of Benefits of Experimental Therapy: A Framework Modeled in Neuroblastoma. Journal of Clinical Oncology, 2013, 31, 641-646.	0.8	9
120	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. Journal of Clinical Oncology, 2013, 31, 2437-2449.	0.8	223
121	The National Cancer Instituteâ€"American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and Recommendations. Journal of Oncology Practice, 2013, 9, 267-276.	2.5	121
122	Ethics and Genomic Incidental Findings. Science, 2013, 340, 1047-1048.	6.0	160
123	Returning genetic research results: study type matters. Personalized Medicine, 2013, 10, 27-34.	0.8	20
124	The first step to integrating the child's voice in adverse event reporting in oncology trials: A content validation study among pediatric oncology clinicians. Pediatric Blood and Cancer, 2013, 60, 1231-1236.	0.8	36
125	Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR). Blood, 2013, 122, 1687-1687.	0.6	3
126	Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
127	Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr. Blood, 2013, 122, 554-554.	0.6	8
128	Sharing of clinical trial data among trialists: a cross sectional survey. BMJ, The, 2012, 345, e7570-e7570.	3.0	112
129	Paying for Tissue: Net Benefitsâ€”Response. Science, 2012, 337, 1293-1293.	6.0	0
130	A Randomized Study of How Physicians Interpret Research Funding Disclosures. New England Journal of Medicine, 2012, 367, 1119-1127.	13.9	165
131	Equipoise: asking the right questions for clinical trial design. Nature Reviews Clinical Oncology, 2012, 9, 230-235.	12.5	28
132	Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey. British Journal of Cancer, 2012, 106, 1021-1026.	2.9	83
133	Recommendations for the Return of Research Results to Study Participants and Guardians: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 4573-4579.	0.8	31
134	Revolution or Reform in Human Subjects Research Oversight. Journal of Law, Medicine and Ethics, 2012, 40, 922-929.	0.4	8
135	Paying Patients for Their Tissue: The Legacy of Henrietta Lacks. Science, 2012, 337, 37-38.	6.0	41
136	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2012, 18, 861-873.	2.0	53
137	Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2012, 18, 903-912.	2.0	43
138	Development of a Test of Residents' Ethics Knowledge for Pediatrics (TREK-P). Journal of Graduate Medical Education, 2012, 4, 242-245.	0.6	15
139	Education in Professionalism: Results from a Survey of Pediatric Residency Program Directors. Journal of Graduate Medical Education, 2012, 4, 101-105.	0.6	25
140	Pediatric oncology research in low income countries: Ethical concepts and challenges. Pediatric Blood and Cancer, 2012, 58, 492-497.	0.8	18
141	â€œEntering a clinical trial: Is it right for you?â€• Cancer, 2012, 118, 1877-1883.	2.0	39
142	Limits to research risks. , 2012, , 36-48.		1
143	Benefit in phase 1 oncology trials. , 2012, , 131-143.		0
144	Equipoise and the Dilemma of Randomized Clinical Trials. , 2012, , 231-240.		0

#	ARTICLE	IF	CITATIONS
145	Evaluating the therapeutic misconception. , 2012, , 243-255.		0
146	Equipoise and the Dilemma of Randomized Clinical Trials. New England Journal of Medicine, 2011, 364, 476-480.	13.9	165
147	A Unique Researcher Identifier for the Physician Payments Sunshine Act. JAMA - Journal of the American Medical Association, 2011, 305, 2007-8.	3.8	14
148	Harmonization of Ethics Policies in Pediatric Research. Journal of Law, Medicine and Ethics, 2011, 39, 70-78.	0.4	13
149	Can RESEARCH and CARE Be Ethically Integrated?. Hastings Center Report, 2011, 41, 37-46.	0.7	85
150	Outcomes of informed consent among parents of children in cancer clinical trials. Pediatric Blood and Cancer, 2011, 57, 998-1004.	0.8	20
151	Protecting the rights and interests of pediatric stem cell donors. Pediatric Blood and Cancer, 2011, 56, 517-519.	0.8	13
152	Reputation and Precedent in the Bevacizumab Decision. New England Journal of Medicine, 2011, 365, e3.	13.9	63
153	Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis. Oncologist, 2011, 16, 1435-1439.	1.9	13
154	Bone Marrow Donation Between Siblings Living in Different Families. Pediatrics, 2011, 127, 158-162.	1.0	10
155	Balancing Access and Evaluation in the Approval of New Cancer Drugs. JAMA - Journal of the American Medical Association, 2011, 305, 2345.	3.8	14
156	Altruism among participants in cancer clinical trials. Clinical Trials, 2011, 8, 616-623.	0.7	101
157	Information Disclosure and the Physician Payments Sunshine Act--Reply. JAMA - Journal of the American Medical Association, 2011, 306, 1087-1088.	3.8	1
158	Considerations About Hastening Death Among Parents of Children Who Die of Cancer. JAMA Pediatrics, 2010, 164, 231.	3.6	38
159	Relationships Between Authorship Contributions and Authors' Industry Financial Ties Among Oncology Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1316-1321.	0.8	31
160	Framing the Benefits of Cancer Clinical Trials. JAMA Pediatrics, 2010, 164, 293.	3.6	2
161	Ethics Consultation in Children's Hospitals: Results From a Survey of Pediatric Clinical Ethicists. Pediatrics, 2010, 125, 742-746.	1.0	53
162	The Impact of Disclosing Financial Ties in Research and Clinical Care. Archives of Internal Medicine, 2010, 170, 675.	4.3	107

#	ARTICLE	IF	CITATIONS
163	Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation. Blood, 2010, 116, 224-224.	0.6	2
164	Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood, 2010, 116, 3509-3509.	0.6	0
165	Is Blood Thicker Than Water?. JAMA Pediatrics, 2009, 163, 413.	3.6	15
166	Limits to research risks. Journal of Medical Ethics, 2009, 35, 445-449.	1.0	59
167	Private Cord Blood Banking: Experiences and Views of Pediatric Hematopoietic Cell Transplantation Physicians. Pediatrics, 2009, 123, 1011-1017.	1.0	65
168	Incidental Findings in Human Subjects Research: What Do Investigators Owe Research Participants?. Journal of Law, Medicine and Ethics, 2008, 36, 271-279.	0.4	96
169	Bench to Bedside: Mapping the Moral Terrain of Clinical Research. Hastings Center Report, 2008, 38, 30-42.	0.7	110
170	CNS Relapse of Acute Myelogenous Leukemia Masquerading as Pseudotumor Cerebri. Pediatric Neurology, 2008, 39, 355-357.	1.0	10
171	Variation in Supportive Care Practices in Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1231-1238.	2.0	51
172	Individual Physician Practice Variation in Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2008, 26, 2162-2170.	0.8	52
173	The Challenge of Research on Ethics Education. American Journal of Bioethics, 2008, 8, 12-13.	0.5	3
174	Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?. Clinical Trials, 2008, 5, 617-623.	0.7	76
175	Parentsâ€™ Views of Cancer-Directed Therapy for Children With No Realistic Chance for Cure. Journal of Clinical Oncology, 2008, 26, 4759-4764.	0.8	95
176	Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy. Journal of Clinical Oncology, 2008, 26, 5994-6000.	0.8	19
177	Pediatricians' Reports of Their Education in Ethics. JAMA Pediatrics, 2008, 162, 368.	3.6	45
178	Knowledge of regulations governing pediatric research: a pilot study. IRB: Ethics & Human Research, 2008, 30, 1-7.	0.8	0
179	Frequency, Type, and Monetary Value of Financial Conflicts of Interest in Cancer Clinical Research. Journal of Clinical Oncology, 2007, 25, 3609-3614.	0.8	33
180	Compact versus Contract â€" Industry Sponsors' Obligations to Their Research Subjects. New England Journal of Medicine, 2007, 356, 2737-2743.	13.9	14

#	ARTICLE	IF	CITATIONS
181	Advance Care Planning in Patients Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 65-73.	2.0	33
182	Clinical Trials and Medical Care: Defining the Therapeutic Misconception. PLoS Medicine, 2007, 4, e324.	3.9	376
183	Children are not small adults: Documentation of assent for research involving children. Journal of Pediatrics, 2006, 149, S31-S33.	0.9	71
184	Involving children with cancer in decision-making about research participation. Journal of Pediatrics, 2006, 149, 862-868.e1.	0.9	81
185	Evaluating the Therapeutic Misconception. Kennedy Institute of Ethics Journal, 2006, 16, 353-366.	0.3	57
186	491-503.	0.9	18
187	Altruistic Discourse and Therapeutic Misconception in Research Informed Consent. American Journal of Bioethics, 2006, 6, 53-54.	0.5	8
188	Rethinking Risk-Benefit Assessment for Phase I Cancer Trials. Journal of Clinical Oncology, 2006, 24, 2987-2990.	0.8	75
189	Patients' Views on Financial Conflicts of Interest in Cancer Research Trials. New England Journal of Medicine, 2006, 355, 2330-2337.	13.9	131
190	ASCO Core Values. Journal of Clinical Oncology, 2006, 24, 5780-5782.	0.8	7
191	Directâ€toâ€Consumer Advertising in Oncology. Oncologist, 2006, 11, 217-226.	1.9	42
192	Differences in Medical Decision Making in Adult and Pediatric Hematopoietic Stem Cell Transplantation (HCT).. Blood, 2006, 108, 74-74.	0.6	4
193	Dana-Farber Cancer Institute Ethics Rounds: Life-Threatening Illness and the Desire to Adopt. Kennedy Institute of Ethics Journal, 2005, 15, 385-393.	0.3	1
194	Informed Consent for Medical Treatment and Research: A Review. Oncologist, 2005, 10, 636-641.	1.9	125
195	Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants. Journal of the National Cancer Institute, 2004, 96, 629-632.	3.0	61
196	Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ: British Medical Journal, 2004, 328, 1463.	2.4	22
197	Case Study: Informed Consent from the Doctor?. Hastings Center Report, 2004, 34, 12.	0.7	2
198	Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet, The, 2004, 363, 263-270.	6.3	336

#	ARTICLE	IF	CITATIONS
199	Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood, 2004, 104, 2194-2200.	0.6	84
200	Family Cord Blood Banking: Experience and Views of Pediatric Hematopoietic Stem Cell Transplant Physicians.. Blood, 2004, 104, 3323-3323.	0.6	0
201	Rethink "Affirmative Agreement," but Abandon "Assent". American Journal of Bioethics, 2003, 3, 9-11.	0.5	43
202	What do patients value in their hospital care? An empirical perspective on autonomy centred bioethics. Journal of Medical Ethics, 2003, 29, 103-108.	1.0	108
203	Public dialogue and the boundaries of moral community. Journal of Clinical Ethics, 2003, 14, 101-8.	0.1	4
204	Views of American Oncologists About the Purposes of Clinical Trials. Journal of the National Cancer Institute, 2002, 94, 1847-1853.	3.0	93
205	Chronic Disseminated Intravascular Coagulation and Childhood-Onset Skin Necrosis Resulting From Homozygosity for a Protein C Gla Domain Mutation, Arg15Trp. Journal of Pediatric Hematology/Oncology, 2002, 24, 685-688.	0.3	6
206	Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet, The, 2001, 358, 1772-1777.	6.3	578
207	Quality of Informed Consent: a New Measure of Understanding Among Research Subjects. Journal of the National Cancer Institute, 2001, 93, 139-147.	3.0	349
208	Inflammatory Bowel Disease Associated With Immune Thrombocytopenic Purpura in Children. Journal of Pediatric Gastroenterology and Nutrition, 2001, 33, 582-587.	0.9	17
209	Costs and Respiratory Syncytial Virus. Pediatrics, 2001, 107, 608-609.	1.0	2
210	The Critical Role of Population-Based Epidemiology in Cost-Effectiveness Research. Pediatrics, 2000, 105, 862-863.	1.0	2
211	Rehospitalization in the First Two Weeks After Discharge From the Neonatal Intensive Care Unit. Pediatrics, 1999, 104, e2-e2.	1.0	125
212	Rehospitalization for Respiratory Syncytial Virus Among Premature Infants. Pediatrics, 1999, 104, 894-899.	1.0	142
213	Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm Infants. Pediatrics, 1999, 104, 419-427.	1.0	191